STAT+: Novo Nordisk links to telehealth providers for patients seeking Wegovy
Novo Nordisk has taken the next step in selling its drugs directly to patients by pointing them to telehealth providers that can write prescriptions for its popular obesity medication Wegovy. The company now links to select virtual providers on the NovoCare direct-to-patient pharmacy website it launched earlier this year, joining other pharma giants that have […]
Biomedicines, Vol. 13, Pages 2088: Impact of Prolonged Fasting and Refeeding on Enteroendocrine Hormone Expression: One More Piece of the Fasting/Refeeding Metabolic Puzzle
Biomedicines, Vol. 13, Pages 2088: Impact of Prolonged Fasting and Refeeding on Enteroendocrine Hormone Expression: One More Piece of the Fasting/Refeeding Metabolic Puzzle Biomedicines doi: 10.3390/biomedicines13092088 Authors: Gonçalo Nunes Marta Guimarães Sofia B. Oliveira Sofia S. Pereira Francisco Vara-Luiz Ivo Mendes Carolina Palma Cátia Oliveira Jorge Fonseca Introduction: Prolonged fasting induces histological and ultrastructural changes […]
Discovery of Glucagon-Like Peptide-1 and Its Biological Activity—Reply
In Reply We thank Dr Mojsov for her comments on our Viewpoint and for her contributions to the field. In our Viewpoint, we sought to provide a more complete chronology of events surrounding the discoveries related to GLP-1. As we noted, we were working in the Habener laboratory at MGH from 1984 to 1988, and […]
Hims & Hers Health Is Looking to Cash In on This Novo Nordisk Blunder
Hims & Hers Health (NYSE:HIMS) is positioning itself to capitalize on Novo Nordisk’s (NYSE:NVO) mounting struggles in the weight loss market, as the Danish pharmaceutical giant wrestles with declining sales and a CEO change. Novo Nordisk terminated its collaboration with Hims & Hers in May, accusing the telehealth company of “illegal mass compounding” and “deceptive […]
New GLP-1 pill helps people lose 23 pounds in study
Eli Lilly says its new once-daily pill, orforglipron, helped people lose significant weight and lower blood sugar in a late-stage clinical trial.
New GLP-1 Pill Helps People Lose 23 Pounds in Study
By I. Edwards HealthDay ReporterWEDNESDAY, Aug. 27, 2025 (HealthDay News) — Eli Lilly says its new once-daily pill, orforglipron, helped people…
The big wins defining value-driven pharmacy today
Becker’s asked pharmacy executives from hospitals and health systems across the U.S. to share their most recent value-driven wins. The 5 executives featured in this article are all speaking at the Becker’s Healthcare Fall Chief Pharmacy Officer Summit, from Nov. 5-6, 2025 at the Hilton Chicago. To learn more about this event, click here. If […]
JCM, Vol. 14, Pages 6060: Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease
JCM, Vol. 14, Pages 6060: Treatment Landscape of Metabolic-Dysfunction-Associated Steatotic Liver Disease Journal of Clinical Medicine doi: 10.3390/jcm14176060 Authors: Pranav Patel Background/Objectives: The incidence of metabolic-dysfunction-associated steatotic liver disease (MASLD) is on the rise worldwide. The purpose of this paper is to review the current and emerging trends in the management and treatment of this […]
Eli Lilly (LLY) Prepares for Weight Loss Pill Approval After Late-Stage Clinical Trial – TipRanks
Eli Lilly (LLY) Prepares for Weight Loss Pill Approval After Late-Stage Clinical Trial TipRanks Eli Lilly Ready to Seek Obesity Pill Green Light After Study Hits Goals The Wall Street Journal Eli Lilly’s weight loss pill orforglipron clears its latest trial, paving way for approval CNBC Eli Lilly’s oral GLP-1 pill may help people with Type 2 diabetes […]
GLP-1s and cancer: What to know
As researchers study the efficacy of GLP-1s like Ozempic and Mounjaro in treating dementia and other health issues with an eye toward expanding their usage, oncologists are looking at a GLP-1 role in cancer care. Several studies have shown the therapies — currently approved for Type 2 diabetes, weight loss, cardiovascular disease, kidney disease, liver […]